<DOC>
	<DOC>NCT00558571</DOC>
	<brief_summary>Primary objective: safety and tolerability of BI 10773 in male and female patients with type 2 diabetes Secondary objective: pharmacokinetics and pharmacodynamics of BI 10773</brief_summary>
	<brief_title>4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Male and postmenopausal or hysterectomised female patients with type 2 diabetes Age &gt;18 and &lt; 70 years BMI &gt;18.5 and &lt;40 kg/m2 Antidiabetic treatment with insulin or glitazones or with more than one oral hypoglycaemic agent; Fasted blood glucose &gt; 240 mg/dl (&gt;13.3 mmol/L) or a blood glucose level above 400 mg/dl (22.2 mmol/L) postprandially; HbA1c &gt; 8.5 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>